Relmada Therapeutics recently disclosed that its phase 3 second-line study targeting BCG non-responsive patient groups is expected to yield preliminary 3-month efficacy data by the end of 2026.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This study is a key milestone in the advancement of the company's core pipeline, and its results are closely watched by the industry.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$77,509.43
-0.17%
Ethereum
ETH
$2,316.02
-0.06%
Tether USDt
USDT
$1
-0.03%
XRP
XRP
$1.42
-1.09%
BNB
BNB
$629.26
-1.27%
USDC
USDC
$0.9997
-0.01%
Solana
SOL
$85.99
-0.70%
TRON
TRX
$0.3241
+0.05%
Dogecoin
DOGE
$0.09795
-1.05%
Hyperliquid
HYPE
$41.43
+0.07%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now